| |
 |
 |
| Company Name |
Novartis (Taiwan) Co., Ltd. |
| Protocol Number |
CRFB002ATW02 |
| Title of Study |
A Multicentre, Open-label, Prospective, Non-interventional Study to the Evaluate Safety and Effectiveness, of Multiple Dose Intravitreal Injections (IVI) of Lucentis® (Ranibizumab) in Patients with Exudative Neovascular (wet) Age-Related Macular Degeneration (AMD) over a 12-Month Observational Period under Real Life Conditions (REAL) |
| Primary Objective |
This study is designed to evaluate the effectiveness and tolerability of repeated intravitreal injection of ranibizumab 0.5 mg under real life conditions in Asian patients with subfoveal CNV due to AMD. |
| Number of Sites |
6 |
| Period of Study |
from 2010-07-15 to 2013-12-15 |
| Number of Patients |
300 |
| IRB Approval Date |
8-Mar-2010 |
| Publication Plan / Date |
N/A |
|
|
|
|
